SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety ...

In the press release titled “Rigel Provides Business Update and 2025 Outlook,” Rigel Pharmaceuticals shared some significant financial highlights. For the fourth quarter of 2024, the company ...

Rigel will mail the definitive proxy statement/prospectus to shareholders of record as of the close of business on January 10, 2025. Rigel will hold its Extraordinary General Meeting (the ...

Rigel Pharmaceuticals (RIGL) closed the last trading session at $17.35, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

AUROUS Resources, the South African business that controls the historic Blyvooruitzicht mine, has received regulatory approval to merge with Rigel Resource Acquisition Group, a deal that would pave ...